{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:17:56Z","timestamp":1769149076011,"version":"3.49.0"},"reference-count":26,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"funding"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2021,5,4]]},"DOI":"10.1080\/14737140.2021.1880326","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T09:51:56Z","timestamp":1615456316000},"page":"475-480","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy"],"prefix":"10.1080","volume":"21","author":[{"given":"Marisa C","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Gynecology Oncology, University of California, Orange, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Sutedja","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Gynecology Oncology, University of California, Orange, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishnansu S","family":"Tewari","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Gynecology Oncology, University of California, Orange, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"cit0002","unstructured":"Cancer Statistics Review, 1975\u20132015 - SEER Statistics. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2015\/. Accessed Sept 15, 2020."},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1328055"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2018\/e450s"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1038\/35077232"},{"key":"cit0006","unstructured":"Fda C. ZEJULATM (Niraparib) Capsules, for Oral Use. www.fda.gov\/medwatch. Accessed Sept 14, 2020."},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.05.025"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy181"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30515-7"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.6012"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30029-4"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.11.105"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1038\/nature22396"},{"key":"cit0015","unstructured":"A phase 3 comparison of platinum-based therapy with TSR-042 and niraparib versus Standard of Care (SOC) platinum-based therapy as first-line treatment of stage III or IV nonmucinous epithelial ovarian cancer Full text view ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03602859. Accessed May 15, 2020."},{"issue":"15","key":"cit0016","first-page":"TPS5600","volume":"37","author":"A-C H-B","year":"2019","journal-title":"J Clin Oncol"},{"key":"cit0017","unstructured":"Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer Full text view ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04068753. Accessed Aug 13, 2020."},{"key":"cit0018","unstructured":"A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. Full text view ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03106987. Accessed Dec 5, 2020."},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01924"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.01.011"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1048"},{"key":"cit0022","doi-asserted-by":"crossref","unstructured":"Hope JM, Chen J, Wainszelbaum M, Gupta D. OVARIO: The phase 2, single-arm, open-label study of maintenance therapy with niraparib + bevacizumab in patients with advanced ovarian cancer following response on frontline platinum-based chemotherapy. J Clin Oncol. 2018 May 20;36(15_suppl):TPS5606\u2013TPS5606.","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS5606"},{"key":"cit0023","unstructured":"Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy - Full Text View - ClinicalTrials.gov [Internet]. [cited 2020 May 15]. Available from: Accessed September 16, 2020."},{"key":"cit0024","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-016-0417-1"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.01.024"},{"key":"cit0026","unstructured":"Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer - Full Text View - ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03955471. Accessed September 16, 2020."}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2021.1880326","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T04:54:28Z","timestamp":1620622468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2021.1880326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,4]]}},"alternative-id":["10.1080\/14737140.2021.1880326"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2021.1880326","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-01-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}